市場調查報告書
商品編碼
1371993
2030 年電外科市場預測:按產品類型、用途、最終用戶和地區分類的全球分析Electrosurgery Market Forecasts to 2030 - Global Analysis By Product Type, Application, End User and By Geography |
根據 Stratistics MRC 的數據,2023 年全球電外科市場規模為 68 億美元,預計預測期內年複合成長率為 10.3%,到 2030 年將達到 135 億美元。
電外科手術是一種在外科手術過程中使用電能來切割、凝固和蒸發組織的醫療技術。特殊工具,如電極或燒灼器械,用於將受控的高頻電流傳遞到目標組織。此外,這種能量會產生熱量,根據其模式,它可以像手術刀一樣切割組織或凝固並封閉血管。電外科手術提供精確性和控制,最大限度地減少出血並加快手術過程。因此,它經常用於各個醫療科室的止血、腫瘤切除和組織形成,包括一般外科、皮膚科、婦科和泌尿系統。
根據《全國醫療保健支出項目(2015-2025)》,2015年至2025年美國醫療保健費用預計平均成長5.8%。此外,該國配備人員的醫院床位數量已增至 931,203 張。
微創和非侵入性手術方法比傳統手術越來越受到青睞。微創手術比開放性手術有許多優點,包括恢復更快、術後併發症更少、疼痛更少。此外,這些方法比傳統手術便宜。此外,雷射和電外科技術比傳統手術方法變得越來越普及。發電機和主動電極等電外科工具使這些手術變得更容易、更快捷,從而增加了對其服務的需求。
對組織使用不當的電能進行切割或凝固可能會導致附近組織燒燙傷。此外,電弧可能會無意中損壞物體,並且產生的熱量會產生含有傳染性顆粒的煙霧。此外,患者的潛在醫療問題,例如心律調節器或金屬植入物,也可能受到影響。此外,其他風險包括培訓不足和設備故障。因此,這些因素預計將限制電外科市場的擴張。
政府專注於加強個人醫療保健系統中的醫療基礎設施,特別是重症監護基礎設施,預計將推動包括電外科行業在內的相關市場的成長。此外,許多成熟國家的政府正在採取措施,透過增加基礎設施改善支出和降低醫療保健成本來改善其當前的醫療保健系統。因此,它極大地促進了市場的成長。
手術煙霧已被證明含有有害氣體、蒸氣、顆粒、活細胞和非活細胞材料、病毒和細菌。此外,每年約有 50 萬名醫療保健專業人員吸入手術煙霧,其中包括醫生、護士和外科技術人員。此外,氣喘和氣喘樣症狀是接觸手術煙霧對健康的直接影響,此外還有眼睛、鼻子和喉嚨發炎、頭痛、咳嗽和鼻塞,因此最終將阻礙市場成長。
由於全球醫療保健系統的中斷,COVID-19 大流行對電外科市場產生了負面影響。擇期手術已被推遲或取消,以優先考慮 COVID-19 患者並降低感染風險。此外,醫院面臨財務限制,包括電外科設備在內的資本設備預算被削減。供應鏈中斷和工廠關閉也影響了這些設備的生產和可用性。此外,患者不願尋求非緊急護理進一步減少了對電外科的需求。此外,雖然長期電外科需求仍然強勁,但短期市場受到疫情期間手術量減少和經濟限制等挑戰的阻礙。
電外科發生器部分透過專門的手機和電極產生高頻電流,估計佔據最大佔有率。此外,它還具有功率設定、波形選項和安全系統等功能,這些功能對於調整組織接合的深度和精確度至關重要。這些發生器被外科醫生用於各種治療,從簡單的手術到複雜的手術。此外,技術進步已經開發出更有效率、更安全的電外科發生器,提高了電外科在醫療領域的整體有效性,並逐步推動市場擴張。
預計皮膚科領域在預測期內的年複合成長率最高。皮膚科醫師經常使用電外科手術去除各種皮膚病變,包括痣、疣和皮膚惡性。此外,放射線手術機等專用設備產生的高頻電流可實現精確切割和凝固,從而減少疤痕並加速康復。此外,對於換膚、疤痕矯正等視覺手術,皮膚科醫生也開始採用電外科手術,讓患者能夠治療多種皮膚科問題,同時提供有效的治療,減少術後併發症,凸顯了電外科設備通過提供更好的美學效果的價值。 。因此,這些方面都有助於市場規模的擴大。
北美是一個由慢性病患病上升、微創手術需求增加、電外科器械技術進步、醫院、診所和門診手術中心數量不斷增加以及門診手術偏好不斷變化所驅動的市場,它獲得了最大的市場由於其顯著擴張,在預測期內市場佔有率。
歐洲預計將在預測期內出現有益成長,因為歐洲因其強大的醫療保健系統而成為電外科儀器和技術的重要市場。其他好處包括該地區人口高齡化和慢性病患病上升,增加了手術的需求。此外,歐洲對病人安全和優質醫療保健的重視鼓勵了尖端電外科技術的使用。然而,由於嚴格的法規標準,這些設備是安全有效的。此外,市場受益於持續的研究和創新,這推動歐洲在市場中佔據關鍵地位。
According to Stratistics MRC, the Global Electrosurgery Market is accounted for $6.8 billion in 2023 and is expected to reach $13.5 billion by 2030 growing at a CAGR of 10.3% during the forecast period. Electrosurgery is a medical technique that employs electrical energy to cut, coagulate, or vaporize tissue during surgical procedures. It involves applying controlled, high-frequency electrical currents to the target tissue using specialized tools like electrodes or cautery equipment. Moreover, heat is created by this energy, and depending on its mode, it can either cut through tissue like a scalpel or coagulate and seal blood vessels. Electrosurgery provides accuracy and control, minimizing hemorrhage and speeding up surgical processes. Therefore, it is frequently used to produce hemostasis, remove growths, and shape tissues in a variety of medical specialties, including general surgery, dermatology, gynaecology, and urology.
According to the National Health Expenditure Projections (2015-2025), health expenditure in the US is expected to grow at an average rate of 5.8% from 2015 to 2025. The total number of staffed hospital beds in the country has also increased to 931,203.
The preference for minimally invasive and non-invasive surgical methods over conventional surgical procedures developed over time. Over open surgical methods, minimally invasive surgeries provide a number of advantages, including quicker recovery times, lower post-operative problems, and less pain. Moreover, these methods are less expensive than conventional surgical procedures. Additionally, laser and electrosurgical technologies are becoming more and more popular over traditional surgical methods. Hence, the simplicity and speed with which such surgeries can be performed are made possible by electrosurgery tools like generators and active electrodes, which boost demand for services.
If electrical energy is applied to tissue for cutting or coagulation improperly, it might result in consequences, including burns to tissue nearby. Moreover, electric arcs may unintentionally damage objects, and the heat they generate can cause smoke to be produced that could contain infectious particles. In addition, the patient's underlying medical issues, such as pacemakers or metal implants, can suffer consequences. Furthermore, other risks include inadequate training or broken equipment. Thus, these elements are expected to restrict the market for electrosurgery's expansion.
Government entities' primary focus on enhancing healthcare infrastructure, especially critical care infrastructure, in their individual healthcare systems is anticipated to boost the growth of associated markets, including the electrosurgery industry. Additionally, many sophisticated nations' governments are taking steps to improve their current healthcare systems by raising expenditures on infrastructure improvements and lowering the cost of healthcare. Therefore, significantly drive the market growth.
Surgical smoke has been demonstrated to contain hazardous gases, vapours, particles, viable and non-viable cellular material, viruses, and germs, in addition to being an annoyance due to its offensive odour and ability to obscure the surgeon's view of the surgical site. Additionally, each year, surgical smoke is inhaled by about 500,000 healthcare professionals, including doctors, nurses, and surgical technologists. Furthermore, asthma and symptoms resembling asthma are among the immediate health effects of exposure to surgical smoke, along with eye, nose, and throat irritation, headaches, coughing, and nasal congestion, therefore which eventually hinder market growth.
The COVID-19 pandemic has had a negative impact on the Electrosurgery Market due to disruptions in healthcare systems worldwide. Elective surgeries were postponed or cancelled to prioritize COVID-19 patients and reduce the risk of transmission. Moreover, hospitals faced financial constraints, leading to reduced budgets for capital equipment, including electrosurgical devices. Supply chain disruptions and factory closures also affected the production and availability of these devices. Additionally, patients' reluctance to seek non-urgent medical care further decreased the demand for electrosurgical procedures. Furthermore, while the long-term demand for electrosurgery remains strong, the short-term market faced challenges in terms of reduced procedure volumes and economic constraints during the pandemic which thus hampered the market.
The electrosurgery generators segment is estimated to hold the largest share, due to specialized handpieces and electrodes, these generators produce high-frequency electrical currents. Additionally, they have features including power settings, waveform options, and safety systems, and they are crucial in regulating the depth and accuracy of tissue engagement. These generators are used by surgeons for a variety of treatments, from straightforward operations to complicated ones. Furthermore, Advancements in technology have led to more efficient and safer electrosurgical generators, enhancing the overall effectiveness of electrosurgery in the medical field which gradually propel the market's expansion.
The dermatology segment is anticipated to have highest CAGR during the forecast period. Dermatologists frequently employ electrosurgery to remove various skin lesions, including moles, warts, and skin malignancies. Moreover, the precise cutting and coagulation made possible by high-frequency electrical currents generated by specialist equipment, such as radiosurgery units, reduces scarring and speeds up recovery. Furthermore, for visual operations like skin resurfacing and scar modification, dermatologists also employ electrosurgery, and while addressing a wide range of dermatological problems, this section highlights the value of electrosurgical equipment by providing patients with efficient treatments with fewer postoperative complications and better aesthetic results. Hence, these aspects help in boosting the market size.
North America commanded the largest market share during the extrapolated period owing to the rising prevalence of chronic diseases, rising demand for minimally invasive procedures, technological advancements in electrosurgical instruments, rising number of hospitals, clinics, and ambulatory surgical centers, and shifting preference toward outpatient surgeries which significantly driven the market expansion.
Europe is expected to witness profitable growth over the projection period, owing to the robust healthcare system in Europe makes it an important market for electrosurgical tools and techniques. Additionally, the industry has benefited from the region's aging population and rising prevalence of chronic diseases, driving the need for surgical procedures. Furthermore, Europe prioritizes patient safety and high-quality healthcare, which promotes the use of cutting-edge electrosurgical technology. However, these devices are safe and effective because of the strict regulatory criteria. Additionally, the market gains from ongoing research and innovation, which propels Europe to a significant position in the market.
Some of the key players in the Electrosurgery Market include: AngioDynamics Inc., B. Braun Melsungen AG, Johnson & Johnson Private Limited, Stryker Corporation, Heal Force Bio-meditech Holdings Limited, Smith & Nephew, Bovie Medical Corporation, Boston Scientific Corporation, Medtronic Plc. and Erbe Elektromedizin GmbH.
In September 2023, Boston Scientific Corporation announced it has received U.S. Food and Drug Administration approval for the latest-generation WATCHMAN FLX™ Pro Left Atrial Appendage Closure (LAAC) Device.
In September 2023, Boston Scientific Corporation announced it has entered into a definitive agreement to acquire Relievant Medsystems, Inc., a privately held medical technology company that has developed and commercialized the Intracept® Intraosseous Nerve Ablation System to treat vertebrogenic pain, a form of chronic low back pain.
In May 2023, Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced that it has entered into a worldwide collaboration and license agreement with Cellular Biomedicine Group Inc. (CBMG) to develop, manufacture and commercialize next-generation chimeric antigen receptor (CAR) T-cell therapies for the treatment of B-cell malignancies.